Lymphomatoid Papulosis: Diagnosis and Treatment

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the mildest of the indolent, cutaneous t-cell lymphomas. These lesions are actually benign (not harmful), although they have T-cells that resemble abnormal tumors in lymphomas. Most patients don’t have lymphoma when they are diagnosed with this conditon; only 20% of patients with lymphomatoid papulosis (LyP) develop more extensive lymphoma at any point in their lifetime (before, during, or after diagnosis).

The incidence of this disease in the United States is 1.9 cases per one million people, so it is extremely rare. Hodgkin’s disease, mycosis fungoides, and large cell lymphoma are associated with the disease for patients who are, in fact, diagnosed with lymphoma.

Diagnosis of Lymphomatoid Papulosis

Patients present with raised bumps on the skin that may develop into blood or pus-filled blisters. These papules (lesions) may become crusty or itchy. They are usually found on the chest, back, stomach, arms or legs. Lesions usually heal on their own within a few weeks of their appearance, and they leave behind no visual scarring.

A diagnosis is made via skin biopsy. The lesions may be type A, type B, or type C, depending on their appearance.

Treatment for Lymphomatoid Papulosis

Since these lesions typically heal on their own, there is no cure for the disease. Some topical treatments have been used in clinical trials, as well as the chemotherapy agent methotrexate. However, these treatments only ease symptoms until the body heals on its own. This can take several years.

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap